You are here

  • Home
  • Archive
  • Volume 9, Issue 2
  • Short-term response to immune-chemotherapy and immune features of a ceritinib-resistant patient with ROS1-rearranged lung adenocarcinoma

Article info

Article menu

Download PDFPDF

XML
Case report
Short-term response to immune-chemotherapy and immune features of a ceritinib-resistant patient with ROS1-rearranged lung adenocarcinoma

Authors

  • Dongsheng Yue Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China PubMed articlesGoogle scholar articles
  • Juanjuan Qian Genecast Biotechnology Co., Ltd, Wuxi, China PubMed articlesGoogle scholar articles
  • Zhipeng Chen Key Laboratory of Functional Protein Research of Guangdong, Higher Education Institutes and MOE Key Laboratory of Tumor Molecular Biology, Institute of Life and Health Engineering, Jinan University, Guangzhou, China PubMed articlesGoogle scholar articles
  • Bin Zhang Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China PubMed articlesGoogle scholar articles
  • Peng Chen Genecast Biotechnology Co., Ltd, Wuxi, China PubMed articlesGoogle scholar articles
  • Lei Zhang Genecast Biotechnology Co., Ltd, Wuxi, China PubMed articlesGoogle scholar articles
  • Jingjing Li Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China PubMed articlesGoogle scholar articles
  • Henghui Zhang Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China PubMed articlesGoogle scholar articles
  • Changli Wang Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Changli Wang; wangchangli{at}tjmuch.com; Dr Henghui Zhang; zhhbao{at}ccmu.edu.cn
View Full Text

Citation

Yue D, Qian J, Chen Z, et al
Short-term response to immune-chemotherapy and immune features of a ceritinib-resistant patient with ROS1-rearranged lung adenocarcinoma
Journal for ImmunoTherapy of Cancer 2021;9:e001967. doi: 10.1136/jitc-2020-001967

Publication history

  • Accepted December 28, 2020
  • First published February 8, 2021.
Online issue publication 
January 26, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.